早期非小细胞肺癌常用立体定向放疗剂量分割方案的肿瘤控制与毒性
该单中心回顾性研究分析了2003至2012年600例早期非小细胞肺癌患者的立体定向放疗剂量与结局。3次分割54-60 Gy组2年局部失败率4.3%,显著低于单次30-34 Gy组的21%、4-5次48-50 Gy组的15.5%及8-10次50-60 Gy组的13.3%。但3次分割组肺毒性和胸壁毒性也略高,且淋巴结失败、远处失败和总生存各组相似。
要点
- 3次分割54-60 Gy组2年局部失败率4.3%,显著低于其他分割方案。
- 3次分割组任何级别肺毒性5.0%、胸壁毒性23.7%,均略高于其他方案。
- 各组淋巴结失败、远处失败和总生存无差异。
核心结论
- 较高生物等效剂量SBRT(150-180 Gy10)可能与略低的局部失败相关,但也伴随轻度增加的毒性,且其他失败模式和总生存无差异。
研究设计与样本
- 单中心回顾性系列,纳入2003至2012年接受SBRT治疗的600例早期非小细胞肺癌患者。
- SBRT剂量由医生根据肿瘤大小和位置决定,外周肿瘤采用60 Gy/3次(均质计划)、48-50 Gy/4-5次或30-34 Gy/1次,中央肿瘤采用50 Gy/5次、60 Gy/8次或50 Gy/10次。
- 分析患者、肿瘤和治疗因素对失败模式、毒性和生存的影响。
主要发现
- 3次分割54-60 Gy组2年局部失败率为4.3%,显著低于单次30-34 Gy组的21%、4-5次48-50 Gy组的15.5%和8-10次50-60 Gy组的13.3%。
- SBRT前较低血红蛋白和较高PET标准化摄取值也与局部失败相关。
- 淋巴结失败、远处失败和总生存在各分割组间相似。
- 任何级别肺毒性粗发生率:3次分割组5.0%,单次组3.2%,4-5次组3.8%。
- 胸壁毒性:3次分割组23.7%,单次组8.6%,4-5次组7.7%。
临床怎么用
- 对于外周早期非小细胞肺癌,3次分割54-60 Gy方案可获得更优的局部控制,但需关注肺和胸壁毒性风险。
- 选择SBRT剂量分割时需权衡局部控制获益与毒性增加,尤其对于靠近胸壁或肺功能受限的患者。
局限性
- 单中心回顾性研究,剂量选择非随机,存在选择偏倚。
- 毒性为粗发生率,未按时间或竞争风险调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the impact of stereotactic body radiation therapy (SBRT) dose on outcomes in early-stage non-small cell lung cancer in a large single-institution series. METHODS AND MATERIALS: We reviewed 600 patients treated from 2003 to 2012 for early-stage non-small cell lung cancer. The SBRT dose was at physician discretion on the basis of tumor size and location. Peripheral tumors were treated to 60 Gy in 3 fractions (homogeneous planning), 48-50 Gy in 4-5 fractions, or 30-34 Gy in 1 fraction. Central tumors were treated to 50 Gy in 5 fractions, 60 Gy in 8 fractions, or 50 Gy in 10 fractions. Patient, tumor, and treatment factors were assessed for their impact on patterns of failure, toxicity, and survival. RESULTS: An SBRT dose of 54-60 Gy in 3 fractions was associated with a statistically significant lower rate of local failure (LF) (4.3% at 2 years) compared with 30-34 Gy in 1 fraction (21%), 48-50 Gy in 4-5 fractions (15.5%), and 50-60 Gy in 8-10 fractions (13.3%). Lower pre-SBRT hemoglobin and higher positron emission tomography standardized uptake value were also associated with LF. Nodal failure, distant failure, and overall survival were similar between fractionation groups. Pulmonary toxicity (crude rate, any grade) was slightly higher for 3 fractions (5.0%) compared with 1 (3.2%) or 4-5 fractions (3.8%). Chest wall toxicity was also higher for 3 (23.7%) compared with 1 (8.6%) or 4-5 (7.7%) fraction regimens. CONCLUSIONS: Although higher biologically equivalent dose SBRT (150-180 Gy10) may be associated with slightly lower LF, it was also associated with mildly increased toxicity and no difference in other patterns of failure or overall survival.
引用
- Stephans KL, Woody NM, Reddy CA, et al. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29353658. doi:10.1016/j.ijrobp.2017.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。